A Safety Study of Retinal Gene Therapy for Choroideremia With Administration of BIIB111

Completed · Phase 2

Conditions studied: Choroideremia

In brief

The objective of the study is to evaluate the safety of bilateral, sequential sub-retinal administration of a single dose of BIIB111 in adult male participants with Choroideremia (CHM).

Key facts

Study ID

NCT03507686

Run by

Biogen

People needed

66

Starts

2017-11-29

Expected to finish

2022-06-29

Last updated by the study team

2024-02-23

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

Where it is running

• Research Site — Miami, Florida, United States
• Research Site — Boston, Massachusetts, United States
• Research Site — Cincinnati, Ohio, United States
• Research Site — Portland, Oregon, United States
• Research Site — Paris, France
• Research Site — Tübingen, Germany

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.